Semaglutide: Ozempic, Wegovy, and Rybelsus Explained

What Is Semaglutide?

Semaglutide is a synthetic peptide that mimics glucagon-like peptide-1 (GLP-1), a hormone the gut releases after a meal. It is manufactured by Novo Nordisk and sold under three FDA-approved brand names, each with a distinct formulation, approved dose, and indication 1Ref 1Aroda VR, Blonde L, Pratley RE (2023).Semaglutide.FDA-approved indications, BMI eligibility criteria, mechanism of action (GLP-1 receptor pathways), contraindications (MTC/MEN 2), side-effect frequency (nausea 44% Wegovy, 20% Ozempic), Black Box Warning on thyroid tumors:

• Ozempic — weekly subcutaneous injection, approved December 2017 for type 2 diabetes management and cardiovascular risk reduction in adults with established heart disease
• Wegovy — weekly subcutaneous injection at a higher dose (up to 2.4 mg/week), approved June 2021 for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition
• Rybelsus — once-daily oral tablet, approved September 2019 for type 2 diabetes; the first oral GLP-1 receptor agonist

Although all three products contain the same active ingredient, their dosing, approved uses, and insurance coverage differ meaningfully.

How Semaglutide Works

Semaglutide's structure was engineered for a half-life of roughly 160 hours — far longer than the body's own GLP-1, which lasts about two minutes — enabling once-weekly dosing 1Ref 1Aroda VR, Blonde L, Pratley RE (2023).Semaglutide.FDA-approved indications, BMI eligibility criteria, mechanism of action (GLP-1 receptor pathways), contraindications (MTC/MEN 2), side-effect frequency (nausea 44% Wegovy, 20% Ozempic), Black Box Warning on thyroid tumors. It acts through three simultaneous pathways:

1. Pancreas: Stimulates insulin release when blood sugar is elevated and suppresses glucagon, which otherwise raises blood sugar. 2. Brain: Acts on appetite-regulating centers in the hypothalamus to reduce hunger and increase satiety. 3. Stomach: Slows gastric emptying so food stays in the stomach longer, blunting post-meal glucose spikes.

In people with type 2 diabetes, the net effect is a mean HbA1c reduction of up to 1.8 percentage points 1Ref 1Aroda VR, Blonde L, Pratley RE (2023).Semaglutide.FDA-approved indications, BMI eligibility criteria, mechanism of action (GLP-1 receptor pathways), contraindications (MTC/MEN 2), side-effect frequency (nausea 44% Wegovy, 20% Ozempic), Black Box Warning on thyroid tumors. At the higher Wegovy dose, the appetite-suppressing effect produces clinically significant weight loss.

What the Clinical Trials Show

Weight loss (STEP 1 trial): In the landmark STEP 1 trial, 1,961 adults with obesity or overweight — but without type 2 diabetes — were randomized to once-weekly semaglutide 2.4 mg or placebo for 68 weeks, alongside lifestyle counseling. The semaglutide group lost a mean 14.9% of body weight versus 2.4% with placebo (treatment difference −12.4 percentage points; 95% CI −13.4 to −11.5; p < 0.001). Eighty-six percent of participants on semaglutide lost at least 5% of body weight, compared with 32% on placebo 2Ref 2Wilding JPH, Batterham RL, Calanna S, et al., STEP 1 Study Group (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.STEP 1 trial primary result: −14.9% body weight in semaglutide group vs −2.4% placebo at 68 weeks (p<0.001); 86.4% achieved ≥5% weight loss vs 31.5% placebo.

Cardiovascular outcomes (SELECT trial): In 2023, the SELECT trial enrolled 17,604 adults with established cardiovascular disease, overweight or obesity, but no diabetes. Semaglutide 2.4 mg reduced the composite rate of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 20% compared with placebo over a mean follow-up of 40 months (HR 0.80, 95% CI 0.72–0.90; p < 0.001) 3Ref 3Lincoff AM, Brown-Frandsen K, Colhoun HM, et al., SELECT Trial Investigators (2023).Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes.SELECT trial: semaglutide reduced MACE by 20% vs placebo (HR 0.80, 95% CI 0.72–0.90, p<0.001) in 17,604 adults with CVD and obesity without diabetes over 40 months mean follow-up; basis for March 2024 FDA cardiovascular indication. This finding led to FDA approval of Wegovy for cardiovascular risk reduction in adults with heart disease and obesity in March 2024.

What happens when semaglutide is stopped: Weight loss reverses after discontinuation. In the STEP 1 extension, participants who stopped after 68 weeks regained a mean 11.6 percentage points over the following year, ending with a net loss of only 5.6% from baseline; those who continued treatment maintained the full loss 4Ref 4Wilding JPH, Batterham RL, Davies M, et al. (2022).Weight Regain and Cardiometabolic Effects after Withdrawal of Semaglutide: The STEP 1 Trial Extension.After stopping semaglutide, mean weight regain of 11.6 percentage points over one year; net loss at week 120 only 5.6% from baseline vs 17.3% at end of active treatment. The STEP 4 trial confirmed a similar pattern after participants switched to placebo 5Ref 5Rubino D, Abrahamsson N, Davies M, et al. (2021).Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.STEP 4 trial: switching from semaglutide to placebo after 20 weeks led to weight regain of 6.9% over subsequent 48 weeks vs continued semaglutide group which lost an additional 7.9%; 14.8 percentage-point difference between groups at end of study. This parallels other chronic-disease medications: the benefit persists only with ongoing treatment.

Side Effects

The most common side effects of semaglutide are gastrointestinal and occur most often at the start of treatment or after a dose increase 1Ref 1Aroda VR, Blonde L, Pratley RE (2023).Semaglutide.FDA-approved indications, BMI eligibility criteria, mechanism of action (GLP-1 receptor pathways), contraindications (MTC/MEN 2), side-effect frequency (nausea 44% Wegovy, 20% Ozempic), Black Box Warning on thyroid tumors:

• Nausea — reported in about 44% of Wegovy users and 20% of Ozempic users; usually peaks in the first 4–8 weeks
• Diarrhea, vomiting, constipation, abdominal pain — each occurring in a substantial minority of users

GI side effects are the leading reason people discontinue semaglutide; they generally improve as the body adjusts to the dose.

Serious but less common risks: - Pancreatitis — acute inflammation; seek care immediately if severe abdominal pain develops - Gallbladder disease — including gallstones and cholecystitis, at higher rates than placebo - Acute kidney injury — typically from dehydration secondary to persistent vomiting or diarrhea - Diabetic retinopathy worsening — reported in people with pre-existing eye disease who experience rapid HbA1c improvement - Increased heart rate — a modest mean increase of 5–10 beats per minute

FDA Black Box Warning: Animal studies showed semaglutide caused thyroid C-cell tumors. Whether this applies to humans is unknown. Semaglutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1Ref 1Aroda VR, Blonde L, Pratley RE (2023).Semaglutide.FDA-approved indications, BMI eligibility criteria, mechanism of action (GLP-1 receptor pathways), contraindications (MTC/MEN 2), side-effect frequency (nausea 44% Wegovy, 20% Ozempic), Black Box Warning on thyroid tumors.

Semaglutide is also contraindicated during pregnancy.

Ozempic vs. Wegovy vs. Rybelsus: Which Is Which?

All three brands contain semaglutide, but dose, indication, and insurance coverage differ.

| Brand | Route | Max dose | Primary approved use | |---|---|---|---| | Ozempic | Injection | 2 mg/week | Type 2 diabetes | | Wegovy | Injection | 2.4 mg/week | Chronic weight management | | Rybelsus | Oral tablet | 14 mg/day | Type 2 diabetes |

Ozempic is prescribed off-label for weight loss because it contains the same molecule as Wegovy, but its maximum dose (2 mg/week) is lower than Wegovy's 2.4 mg maintenance dose. Insurers have grown stricter about covering Ozempic for weight loss without a diabetes diagnosis.

Rybelsus uses a special absorption technology to survive the stomach. It must be taken on an empty stomach with no more than 4 oz of plain water, followed by a 30-minute fast before eating or taking other medications. Weight loss with Rybelsus at the 14 mg dose is more modest than with injectable Wegovy.

Who May Be a Candidate

Prescribers consider Wegovy for adults whose BMI is 30 or above, or 27 or above with at least one weight-related health condition such as hypertension, high cholesterol, type 2 diabetes, or obstructive sleep apnea 1Ref 1Aroda VR, Blonde L, Pratley RE (2023).Semaglutide.FDA-approved indications, BMI eligibility criteria, mechanism of action (GLP-1 receptor pathways), contraindications (MTC/MEN 2), side-effect frequency (nausea 44% Wegovy, 20% Ozempic), Black Box Warning on thyroid tumors. For Ozempic and Rybelsus, the primary indication is type 2 diabetes management.

Semaglutide is not appropriate for: - People with a personal or family history of MTC or MEN 2 syndrome - Women who are pregnant or planning pregnancy - People with type 1 diabetes - Those with a history of serious hypersensitivity to semaglutide

A clinician evaluates the full picture — cardiovascular history, other medications, kidney function, and insurance coverage — before determining whether semaglutide is the right fit.

Cost and Insurance

Without insurance, Wegovy lists at roughly $1,300–$1,400 per month and Ozempic at $900–$970 per month (a 4-week supply). No generic is available in the United States.

Insurance coverage for weight-loss use is inconsistent — many employer plans exclude GLP-1 drugs for obesity. Coverage expanded after the SELECT trial led to Wegovy's cardiovascular indication in 2024. As of 2026, Medicare Part D covers Wegovy for enrollees with established cardiovascular disease but not for weight loss alone.

Cost-reduction options to discuss with a prescriber: - Novo Nordisk's NovoCare savings card for commercially insured patients - Patient assistance programs for households below 400% of the federal poverty level